MedTrace Logo

MMRF CureCloud Research Initiative

NCT03657251 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1105

Last updated 2024-01-05

No results posted yet for this study

Summary

The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data aggregated with the correlating clinical information. Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Through the consenting process, participants will also be authorizing collection of their electronic medical records information.

Conditions

Interventions

GENETIC

liquid biopsy

Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.

Sponsors & Collaborators

  • Multiple Myeloma Research Foundation

    lead OTHER

Principal Investigators

  • Hearn J Cho, MD, PhD · Multiple Myeloma Research Foundation

  • George Mulligan, PhD · Multiple Myeloma Research Foundation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2023-12-29
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657251 on ClinicalTrials.gov